News
RGLS
2.270
+1.79%
0.040
Analyst Maintains ‘Buy’ Rating on Regulus Amid Positive Developments for RGLS8429 in ADPKD Treatment
TipRanks · 21h ago
Buy Rating Affirmed for Regulus’s Innovative ADPKD Therapy RGLS8429
TipRanks · 1d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Agape ATP (NASDAQ:ATPC) shares rose 23.0% to $0.32 during Monday's after-market session. FibroGen shares increased by 20.68% as the Q1 earnings report came out today. The company's market cap stands at $2.6 billion.
Benzinga · 2d ago
Regulus Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co.
Dow Jones · 2d ago
HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $9 Price Target
Benzinga · 2d ago
Optimistic Buy Rating for Regulus Therapeutics’ RGLS8429 Amid Promising ADPKD Treatment Progress
TipRanks · 2d ago
REGULUS THERAPEUTICS ADVANCES TO COHORT 4 OF PHASE 1B MULTIPLE-ASCENDING DOSE (MAD) CLINICAL TRIAL OF RGLS8429 FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
Reuters · 2d ago
Weekly Report: what happened at RGLS last week (0429-0503)?
Weekly Report · 2d ago
Earnings week ahead: Disney, Palantir, Shopify, Uber, Plug Power and more
Earnings week ahead: Disney, Palantir, Shopify, Uber, Plug Power and more are set to report financial results. The Walt Disney Company is scheduled to report its quarterly results on May 7. The first full week of May will see a diverse group of companies report quarterly results.
Seeking Alpha · 3d ago
Weekly Report: what happened at RGLS last week (0422-0426)?
Weekly Report · 04/29 10:27
Weekly Report: what happened at RGLS last week (0415-0419)?
Weekly Report · 04/22 10:21
Weekly Report: what happened at RGLS last week (0408-0412)?
Weekly Report · 04/15 10:15
Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD
Seeking Alpha · 04/10 16:51
Regulus files to sell 62.5M shares of common stock for holders
Healthcare Regulus files to sell 62.5M shares of common stock for holders. Regulus Therapeutics (NASDAQ:RGLS) filed to sell up to an aggregate of 62,500,167 shares ofcommon stock. This prospectus is not an offer to sell these securities.
Seeking Alpha · 04/09 21:06
Weekly Report: what happened at RGLS last week (0401-0405)?
Weekly Report · 04/08 10:18
Weekly Report: what happened at RGLS last week (0325-0329)?
Weekly Report · 04/01 10:17
Buy Rating on Regulus’s RGLS8429 Backed by Positive Phase 1b Data and Unmet ADPKD Treatment Needs
Analyst Whitney Ijem of Canaccord Genuity has maintained a Buy rating on Regulus (RGLS) The company is developing a drug candidate for the treatment of kidney disease ADPKD. The drug candidate, RGLS8429, targets the miR-17 pathway implicated in the disease.
TipRanks · 03/27 11:16
Analysts Offer Insights on Healthcare Companies: Regulus (RGLS), Axsome Therapeutics (AXSM) and Olink Holding (OLK)
TipRanks · 03/27 07:10
Analysts Offer Insights on Healthcare Companies: Regulus (RGLS), Hims & Hers Health (HIMS) and Olink Holding (OLK)
TipRanks · 03/27 07:01
Buy Rating Reaffirmed for Regulus Therapeutics Amid Promising Drug Development Milestones
TipRanks · 03/25 10:26
More
Webull provides a variety of real-time RGLS stock news. You can receive the latest news about Regulus Therapeu through multiple platforms. This information may help you make smarter investment decisions.
About RGLS
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.